Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cell Biotech Co (049960) Fair Value & Analysis

Healthcare · KR · Market cap 112B KRW

Price15,170 KRW
Fair Value19,433 KRW
Upside+28.1%
Quality95/100
Evidence: High Range 13,994 KRW – 26,133 KRW

Fair value as of: Jun 24, 2026

Analysis

Cell Biotech Co (049960) currently trades at 15,170 KRW, while our model-based Fair Value estimate is 19,433 KRW — implying the stock looks roughly 28.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.

Open the full interactive analysis →

Similar stocks

Peptron, Inc (087010) -81% MEDIPOST Co (078160) -37% Bioneer Corporation (064550) +75% Macrogen, Inc (038290) -62% Panagene Inc (046210) +15% Biotoxtech Co (086040) -14%

Frequently asked questions

Is Cell Biotech Co (049960) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 19,433 KRW versus a price of 15,170 KRW — about +28% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 049960?
Our 21-model fair value for Cell Biotech Co is 19,433 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 15,170 KRW.
What is the quality score of 049960?
Cell Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.